APOC3 mutation, serum triglyceride concentrations, and coronary heart disease

Clinical Chemistry

Volumn 55, Issue 7, 2009, Pages 1274-1276

  Tsai, Michael Y ^a,c   Ordovas, José M ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY   (United States)

^c Mayo Mail Code 609   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHYLOMICRON; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PRAVASTATIN; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY CALCIUM LEVEL; DIET THERAPY; EDITORIAL; GENE EXPRESSION REGULATION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; LOSS OF FUNCTION MUTATION; METABOLIC SYNDROME X; PARTICLE SIZE; PRACTICE GUIDELINE; RISK FACTOR; SECONDARY PREVENTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEIN C-III; CORONARY DISEASE; HUMANS; MUTATION; TRIGLYCERIDES;

EID: 67650091466     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.124669     Document Type: Editorial

References (5)

1. Tsai MY, Cao J. Lipoprotein subclass: a changing landscape. Curr Cardiovasc Risk Rep 2008;2:23-8.
2. Bensal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16.
3. Pollin T, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (Wash DC) 2008;322:1702-5.
4. Liu Y, Ordovas JM, Gao G, Province M, Straka RJ, Tsai MY, et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Pharmacogenet Genomics 2009;19:161-9.
5. Cannon CP, Braunwalk E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.